Literature DB >> 11488328

Factors associated with relapse after ambulatory treatment of acute exacerbations of chronic bronchitis. DAFNE Study Group.

M Miravitlles1, C Murio, T Guerrero.   

Abstract

This study aimed to identify the risk factors for relapse after ambulatory treatment of acute exacerbations of chronic bronchitis (AECB) that can easily be used in a primary care setting. Data were prospectively collected on 2,414 ambulatory patients with AECB from 268 general practices located throughout Spain. A multivariate model to identify risk factors independently associated with failures was developed and validated from the information recorded at the inclusion visit and at 30-days follow-up visit. A total of 507 patients relapsed (21%); of these, 84 required admission (16.5%). The multivariate model for prediction of the risk of relapse included 2,414 cases: 1,689 for the developmental sample and 725 in the validation sample. The model obtained contained three readily-obtainable variables: ischaemic heart disease (odds ratio (OR)=1.63; 95% confidence interval (CI)=1.07-2.47), degree of dyspnoea (OR = 1.31; 1.14-1.50) and number of visits to the general practitioner the previous year (OR = 1.07; 1.04-1.10). The model calibrated well in developmental and validation samples (goodness-of-fit tests: p = 0.295 and p = 0.637, respectively). Severity of the exacerbation was not associated with increased risk of relapse in either univariate or multivariate analysis. The present results suggest that baseline characteristics of the patients such as degree of dyspnoea, coexisting ischaemic heart disease and number of previous visits to the general practitioner for respiratory problems are strongly associated with increased risk of relapse after ambulatory treatment of acute exacerbations of chronic bronchitis. In contrast, exacerbation severity was not associated with clinical failure. Guidelines for management of acute exacerbations of chronic bronchitis should consider such risk factors and advocate intensive broad spectrum treatment and closer follow-up of patients exhibiting them.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11488328     DOI: 10.1183/09031936.01.17509280

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  32 in total

Review 1.  COPD exacerbations. 4: Prevention.

Authors:  S Scott; P Walker; P M A Calverley
Journal:  Thorax       Date:  2006-05       Impact factor: 9.139

2.  Intermediate care--Hospital-at-Home in chronic obstructive pulmonary disease: British Thoracic Society guideline.

Authors: 
Journal:  Thorax       Date:  2006-11-07       Impact factor: 9.139

3.  Cost-Effectiveness of Fixed-Dose Combinations Therapies for Chronic Obstructive Pulmonary Disease Treatment.

Authors:  Margarita Capel; María Mareque; Carlos José Álvarez; Leandro Lindner; Itziar Oyagüez
Journal:  Clin Drug Investig       Date:  2018-07       Impact factor: 2.859

4.  Determining factors in the prescription of moxifloxacin in exacerbations of chronic bronchitis in the primary-care setting.

Authors:  Marc Miravitlles; Carles Llor
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

5.  Previous outpatient antibiotic use in patients admitted to hospital for COPD exacerbations: room for improvement.

Authors:  M Miravitlles; J J Soler-Cataluña; F Baranda; P Cordero; J-V Greses; C de la Roza
Journal:  Infection       Date:  2012-08-21       Impact factor: 3.553

6.  Antibiotic treatment of exacerbations of COPD in general practice: long-term impact on health-related quality of life.

Authors:  Marc Miravitlles; Carles Llor; Jesús Molina; Karlos Naberan; Josep M Cots; Fernando Ros
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2010-02-18

7.  Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study.

Authors:  M Miravitlles; M Ferrer; A Pont; R Zalacain; J L Alvarez-Sala; F Masa; H Verea; C Murio; F Ros; R Vidal
Journal:  Thorax       Date:  2004-05       Impact factor: 9.139

8.  Incidence and risk factors of exacerbations among COPD patients in primary health care: APMPOC study.

Authors:  Eulàlia Borrell; Mar Rodríguez; Pere Torán; Laura Muñoz; Guillem Pera; Núria Montellà; Mònica Monteagudo; Magalí Urrea; Yolanda Puigfel; Antonio Negrete; Xavier Mezquiriz; Cristina Domènech; Anna Lacasta; Ma Llum García; Sandra Maneus; Glòria Tintoré
Journal:  BMC Public Health       Date:  2009-01-09       Impact factor: 3.295

9.  COPD exacerbation: lost in translation.

Authors:  Demosthenes Makris; Demosthenes Bouros
Journal:  BMC Pulm Med       Date:  2009-01-29       Impact factor: 3.317

10.  Efficacy of amoxycillin versus amoxycillin/clavulanate in acute exacerbations of chronic pulmonary obstructive disease in primary care.

Authors:  Carl Llor; Silvia Hernández; Anna Ribas; Carmen Alvarez; Josep Maria Cots; Carolina Bayona; Isabel González; Marc Miravitlles
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2009-04-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.